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Abstract 
Background: Studies of dipeptidyl peptidase (DPP)-4 inhibitors report heterogeneous effects on endothelial  
function in patients with type 2 diabetes (T2D). This study assessed the effects of the DPP-4 inhibitor linagliptin versus 
the sulphonylurea glimepiride and placebo on measures of macro- and microvascular endothelial function in patients 
with T2D who represented a primary cardiovascular disease prevention population.
Methods: This crossover study randomised T2D patients (n = 42) with glycated haemoglobin (HbA1c) ≤7.5%, no 
diagnosed macro- or microvascular disease and on stable metformin background to linagliptin 5 mg qd, glimepiride 
1–4 mg qd or placebo for 28 days. Fasting and postprandial macrovascular endothelial function, measured using 
brachial flow-mediated vasodilation, and microvascular function, measured using laser-Doppler on the dorsal thenar 
site of the right hand, were analysed after 28 days.
Results: Baseline mean (standard deviation) age, body mass index and HbA1c were 60.3 (6.0) years, 30.3 (3.0) kg/m2 
and 7.41 (0.61)%, respectively. After 28 days, changes in fasting flow-mediated vasodilation were similar between the 
three study arms (treatment ratio, gMean [90% confidence interval]: linagliptin vs glimepiride, 0.884 [0.633–1.235]; 
linagliptin vs placebo, 0.884 [0.632–1.235]; glimepiride vs placebo, 1.000 [0.715–1.397]; P = not significant for all 
comparisons). Similarly, no differences were seen in postprandial flow-mediated vasodilation. However, under fasting 
conditions, linagliptin significantly improved microvascular function as shown by a 34% increase in hyperaemia area 
(P = 0.045 vs glimepiride), a 34% increase in resting blow flow (P = 0.011 vs glimepiride, P = 0.003 vs placebo), and 
a 25% increase in peak blood flow (P = 0.009 vs glimepiride, P = 0.003 vs placebo). There were no significant differ-
ences between treatments in postprandial changes. Linagliptin had no effect on heart rate or blood pressure. Rates 
of overall adverse events with linagliptin, glimepiride and placebo were 27.5, 61.0 and 35.0%, respectively. Fewer 
hypoglycaemic events were seen with linagliptin (5.0%) and placebo (2.5%) than with glimepiride (39.0%).
Conclusions: Linagliptin had no effect on macrovascular function in T2D, but significantly improved microvascular 
function in the fasting state.
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Background
The endothelium plays an important regulatory role 
in maintaining vascular homeostasis. Impairment of 
endothelial function (endothelial dysfunction) is an early 
step in the pathogenesis of atherosclerosis. Endothelial 
dysfunction is closely associated with the development of 
diabetic vascular diseases such as nephropathy, neuropathy 
and retinopathy [1], and is predictive of future cardiovas-
cular events, including cardiovascular mortality [2–4]. 
Understanding and treating endothelial dysfunction is a 
major focus in the prevention of macro- and microvascu-
lar complications associated with type 2 diabetes (T2D) 
[1].
Dipeptidyl peptidase (DPP)-4 inhibitors, one of the 
more recently introduced oral glucose-lowering drug 
classes, have become widely used as they offer advan-
tages over conventional therapies, in terms of their low 
risk for hypoglycaemia and neutral effect on body weight 
[5]. Furthermore, the effects of DPP-4 inhibitors on the 
macro- and microvascular system are of particular inter-
est because, in addition to their glucose-lowering activity, 
they may have pleiotropic properties that potentially confer 
beneficial cardiovascular effects. Several substrates of the 
DPP-4 enzyme, including the incretin hormone gluca-
gon-like peptide-1 and its metabolites, may directly or 
indirectly influence cardiovascular function [6, 7].
To date, several large prospective trials have inves-
tigated the long-term effects of DPP-4 inhibitors on 
cardiovascular outcomes in a secondary prevention set-
ting. In patients with advanced diabetes and at high car-
diovascular risk, no change in the rates of cardiovascular 
outcomes was seen [8–10], although potential beneficial 
effects on the microvasculature such as reduced devel-
opment and progression of microalbuminuria were 
reported [9].
Overall, the effects of DPP-4 inhibitors on clinical 
atherosclerosis remain unclear, especially in patients at 
an early stage of vascular dysfunction. Previous stud-
ies investigating endothelial function have reported 
heterogeneous effects of DPP-4 inhibitors, both in 
healthy volunteers [11, 12] and in patients with T2D 
[13–17]. These heterogeneous results may be attribut-
able to the methods applied and variances in the popu-
lations studied. Furthermore, differences in glucose 
control between study arms could have prevented firm 
conclusions from being drawn about the pleiotropic 
effects of DPP-4 inhibition versus effects resulting from 
the reduction of hyperglycaemia, which is suggested to 
improve endothelial function [18].
In the present study, we assessed the short-term effects 
of the DPP-4 inhibitor linagliptin compared with an 
active comparator (the sulphonylurea glimepiride) and 
with placebo on measures of macro- and microvascular 
endothelial function in healthy patients with uncom-
plicated T2D who were representative of a primary 




This was a randomised, active- and placebo-controlled, 
three-period crossover, 4-week treatment period, 
single-centre clinical trial conducted in Germany 
between November 2012 and January 2014 (Clinical-
Trials.gov identifier: NCT01703286; EudraCT number: 
2012-003317-33).
The study protocol and amendments were approved by 
the independent ethics committee of the trial centre. The 
study was conducted in compliance with the principles of 
the Declaration of Helsinki, and in accordance with Good 
Clinical Practice as defined by the International Confer-
ence on Harmonisation. All patients provided written 
informed consent before study initiation.
Consenting patients with a diagnosis of T2D and no 
diagnosed macro- or microvascular complications, 
18‒70  years of age, with a body mass index (BMI) of 
25‒35 kg/m2 and a glycated haemoglobin (HbA1c) level 
of ≤7.5%, and stable metformin background therapy 
(≥1500 mg/day for at least 3 months) were eligible. The 
main exclusion criteria were: treatment with any glucose-
lowering drug (except metformin) within the previous 
3 months; any laboratory value or finding of the medical 
examination (including blood pressure, pulse rate and 
electrocardiogram) deviating from normal and of clinical 
relevance; history of cardiovascular disease or major dia-
betic complication; evidence of a clinically relevant acute 
concomitant disease; gastrointestinal, hepatic, renal, res-
piratory, cardiovascular, immunological or hormonal dis-
orders that may influence vascular reactivity or glucose 
metabolism (except hypertension, hyperlipidaemia and 
hypothyroidism if treatment was stable for the previous 
3 months); gastrointestinal surgery (except appendectomy); 
diseases of the central nervous system, or psychiatric or 
neurological disorders; history of relevant orthostatic 
Trial registration ClinicalTrials.gov identifier—NCT01703286; registered October 1, 2012
Keywords: Type 2 diabetes, Dipeptidyl peptidase-4 inhibitor, Linagliptin, Sulphonylurea, Endothelial function, 
Macrovascular, Microvascular, Flow-mediated vasodilation
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hypotension, fainting spells or blackouts; chronic or rel-
evant acute infections; history of relevant allergy/hyper-
sensitivity (including allergy to the drug or its excipients); 
intake of drugs with a long half-life (>24 h) within at least 
1 month or less than 10 half-lives of the respective drug 
prior to administration or during the trial. Other exclu-
sion criteria included participation in another trial with 
an investigational drug within the previous month, drug 
or alcohol (>60  g/day) abuse, smoker, blood donation 
and excessive physical activities (within 1  week prior to 
administration or during the trial).
Study procedures
After screening, patients received daily placebo (A), 
glimepiride 1‒4 mg (B), or linagliptin 5 mg (C), in addi-
tion to continuing metformin during each 4-week treat-
ment period. There was a 3-week washout between 
each treatment period to prevent carry-over effects 
(Fig.  1a). Patients were randomised to one of six treat-
ment sequences according to the Williams square design 
(ABC, CBA, BCA, BAC, ACB or CAB) such that every 
patient received each of the three treatments; the block 
size was six. Randomisation was performed using a vali-
dated system which involved a pseudo-random number 
generator and a supplied seed number. Treatments were 
masked using a double-blind and double-dummy design.
For the first week, the starting dosage of glimepiride 
was 1 mg/day. The dosage was then increased to 2 mg/day, 
and could be uptitrated to a maximum dosage of 4 mg/
day if fasting home blood glucose levels were >110 mg/
dL (6.1  mmol/L) on days 14 and 21, unless the risk for 
hypoglycaemia was increased. The dose could be down-
titrated at any time to prevent recurrent hypoglycaemic 
events. No specific rescue drugs were anticipated for the 
treatment of adverse events and no additional treatment 
was planned. If adverse events occurred, the patient was 
to be treated as necessary (as judged by the investigator) 
and kept under constant supervision.
Metformin monotherapy was the only concomi-
tant glucose-lowering treatment permitted. No other 
concomitant therapy was allowed, except for statins, 
angiotensin-converting enzyme (ACE) inhibitors, oral 
contraceptives and ovary and stable thyroid hormone 
replacement. Angiotensin receptor blockers were allowed 
if used within a stable regimen and if they were known to 
have no impact on nitric oxide metabolism.
Endpoints
The primary efficacy endpoint was macrovascular endothe-
lial function under fasting conditions, measured as the 
change from baseline in flow-mediated vasodilation on day 
28. Secondary endpoints were macrovascular endothelial 
function under postprandial (2-h) conditions, measured as 
the change from baseline in flow-mediated vasodilation on 
day 28, and macrovascular endothelial-independent vaso-
dilation under postprandial (2-h) conditions (standard-
ised liquid meal), measured as the change from baseline in 
nitroglycerin-mediated vasodilation on day 28.
Other efficacy endpoints included changes from base-
line on day 28 in the following variables: microvascular 
Fig. 1 a Study design. b Vascular assessments on day 1 and day 28 of the 4-week treatment periods. FMD flow-mediated vasodilation, NMD 
nitroglycerin-mediated vasodilation. *Glimepiride dose uptitration protocol: initial daily dose of 1 mg for 1 week, uptitrated to 2 mg from week 2; 
further uptitration to maximum daily dose of 4 mg was allowed if fasting glucose levels were >110 mg/dL (>6.1 mmol/L) at days 14 and 21, and at 
the investigator’s discretion. †2-h postprandial
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function measured using laser-Doppler under fasting and 
postprandial conditions; macrovascular function bio-
marker levels (soluble P-selectin, E-selectin, von Wille-
brand factor) under fasting conditions; systemic nitric 
oxide metabolite levels (nitrates, nitrites) under fasting and 
postprandial conditions; levels of plasma glucose and insu-
lin; lipid metabolism (levels of triglycerides, low-density 
lipoprotein [LDL], high-density lipoprotein [HDL], free 
fatty acids); 24-h continuous blood pressure monitoring.
Endpoints of safety included the frequency and inten-
sity of adverse events. Other safety endpoints were: 
physical examination; vital signs (systolic and diastolic 
blood pressure [SBP and DBP], pulse rate); clinical labo-
ratory tests. The following pre-specified adverse events of 
special interest were reported: hepatic injury (an eleva-
tion of aspartate transferase and/or alanine transferase 
levels of ≥threefold the upper level of normal [ULN] 
combined with an elevation of total bilirubin of ≥two-
fold ULN measured in the same blood sample); hyper-
sensitivity reactions (e.g., angioedema, angioedema-like 
events or anaphylaxis); skin lesions (e.g., exfoliative rash, 
skin necrosis or bullous dermatitis); renal adverse events 
(e.g., acute renal failure, a ≥twofold increase in creati-
nine levels); pancreatitis. Hypoglycaemia was defined as 
blood glucose levels of ≤70 mg/mL (≤3.9 mmol/L), with 
or without typical symptoms; severe hypoglycaemia was 
defined as requiring the assistance of another person 
to administer resuscitative actions. Version 16.1 of the 
Medical Dictionary for Regulatory Activities (MedDRA) 
was used to code adverse events.
Vascular assessments
At the start (day −1) and end (day 28) of each 4-week 
treatment period, vascular assessments were performed 
after fasting for at least 10 h and then 2 h after a liquid 
meal test (Ensure® Plus drink, Abbott) (Fig. 1b).
The ultrasound procedures for assessing flow-mediated 
vasodilation of the brachial artery were carried out on the 
right arm with patients in the supine position (unless there 
were valid reasons to use the left arm). Measurements were 
made after a 10-min rest in a quiet dark room at a temper-
ature of approximately 22 °C. A high-resolution ultrasound 
scanner with a 12.0-MHz linear array transducer was used 
(General Electric Vivid 7; GE Healthcare, Milwaukee, WI, 
USA). The brachial artery was scanned longitudinally, just 
above the antecubital crease. To ensure good reproducibil-
ity of repeat measurements, the patient’s anatomic mark-
ers and the transducer position were utilised.
To assess endothelium-dependent vasodilation, base-
line diameter measurements were obtained. Arterial 
occlusion was then performed by inflating a forearm 
blood pressure cuff (12.5 cm wide) to 50 mmHg above the 
SBP for 5 min. Diameter changes were expressed as the 
percentage change relative to the mean baseline value. A 
computer system with automated tracing of echo inter-
faces and measurements of distances between the wall 
echoes within a defined section of the brachial artery was 
used. Images obtained during vascular assessments were 
digitally acquired and were evaluated offline with a dedi-
cated software tool (Vascular Research Tools 5, Medical 
Imaging Applications, LLC, USA). Brachial artery diame-
ter was calculated in diastolic frames taken coincidentally 
with the R wave on the electrocardiogram between 60 
and 90 s after cuff deflation. The maximum diameter of 
these measurements compared with the baseline diam-
eter was used for analysis. Flow-mediated vasodilation 
was defined as the percentage increase in artery diam-
eter during hyperaemia (100 × [(diameter after hyperae-
mia − baseline diameter)/baseline diameter]).
After a 10-min rest, endothelial-independent vasodilation 
was assessed under 2-h postprandial conditions. Bra-
chial artery scans were obtained at baseline and 5  min 
after administration of sublingual nitroglycerin (0.4  mg 
glyceryl trinitrate, an exogenous nitric oxide donor). 
Nitroglycerin-mediated vasodilation was defined as the 
maximum percentage increase in vessel diameter after 
nitroglycerin administration.
Microvascular function was assessed using laser-Doppler 
flowmetry (PF5000; Perimed AB, Järfälla, Sweden) to meas-
ure blood flow on the dorsal thenar site of the right hand, 
which was quantified as arbitrary perfusion units (as laser-
Doppler flowmetry cannot measure absolute blood flow). 
Measurement variables were the pre-ischaemia blood flow 
(resting blood flow) and maximal post-ischaemia blood 
flow during reactive hyperaemia (peak blood flow) after 
5  min of suprasystolic ischaemia of the forearm (Addi-
tional file 1: Figure S1). The reactive hyperaemia reflects the 
endothelium-dependent vasoreactivity of the microcircu-
lation. Reactive hyperaemia was defined as the area under 
the curve of blood flow measured continuously over 120 s 
after cuff release. The parameters described above were cal-
culated using commercially available software (PeriSoft for 
Windows 2.50; Perimed AB, Järfällä, Sweden).
Statistical analysis
This was a hypothesis-generating trial and, therefore, 
all statistical evaluations should be considered descrip-
tive and not inferential. SAS version 9.2 was used for 
all analyses. The trial was planned to include a total of 
42 patients. Allowing for up to six patients to drop out 
during the trial, N = 36 was used as the sample size for 
precision calculations. An estimated standard deviation 
(SD) of approximately 3% for flow-mediated vasodilation 
measurements was assumed for the trial site (Profil Insti-
tut für Stoffwechselforschung GmbH, Neuss, Germany) 
and, given the sample size of 36 patients, the precision of 
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the two-sided 90% confidence interval (CI) of the flow-
mediated vasodilation population effect was calculated 
to be approximately 1.027 (upper confidence limit/lower 
confidence limit). For a greater SD of 3.5%, the precision 
would still be approximately 1.032.
An analysis of variance (ANOVA) model was used 
for the primary efficacy endpoint. This model included 
“patients within sequences” as a random effect and 
“sequence”, “period” and “treatment” as fixed effects. 
The change from baseline was calculated as the value on 
day 28 minus the respective value at baseline, and was 
expressed as the ratio of fasting flow-mediated vasodila-
tion on day 28 to baseline fasting flow-mediated vasodi-
lation. Baseline was the mean of fasting flow-mediated 
vasodilation values on day −1 across all three treatment 
periods. For the secondary endpoints and measures of 
microvascular function, change from baseline on day 28 
in postprandial flow-mediated vasodilation and nitro-
glycerin-mediated vasodilation was analysed with an 
ANOVA in the same way as the primary endpoint.
Point estimates of the primary and secondary end-
points and their two-sided 90% CIs were reported. For 
each endpoint, the difference between the expected 
means was estimated using the difference in the corre-
sponding adjusted means and a two-sided 90% CI based 
on the t-distribution was computed. In addition, the 
influence of the patient’s age on the primary and second-
ary endpoints was evaluated using a sensitivity analysis 
(analysis of covariance, ANCOVA) by additionally adjust-
ing the ANOVA by age.
Efficacy data were analysed in the efficacy set of 
patients, which included all patients in the treated set 
(see below) who provided at least one observation for at 
least one primary, secondary or other efficacy endpoint 
without important protocol violations relevant for the 
statistical evaluation of these endpoints.
Safety data were analysed in the treated set of patients, 
which included all patients who received study medi-
cation and took at least one dose of study drug. Safety 
analyses were summarised descriptively and based on the 
number of patients with an adverse event (frequency). 
For laboratory data (including nitric oxide metabolites 
and vascular biomarkers) and vital signs, the differences 
from baseline were evaluated using descriptive statistics. 
Baseline was the last measurement before first trial drug 
intake in each treatment period.
Results
Patient disposition and baseline characteristics
A total of 60 patients were screened; of these, 42 patients 
were randomised. Three patients discontinued treat-
ment: one patient because of an adverse event (pruritic 
rash; discontinued in period 2—placebo); two patients 
withdrew consent (one patient withdrew during period 
1—linagliptin; one patient withdrew during washout 
after period 1—glimepiride). Forty patients entered the 
placebo and linagliptin treatment periods; 41 patients 
entered the glimepiride period. All 42 randomised 
patients were included in the treated set; 41 patients were 
included in the efficacy set.
Demographics and clinical characteristics at baseline 
for the treated set of patients are presented in Table  1. 
Mean age was 60.3  years (SD 6.0, range 46−70  years) 
and mean BMI was 30.3  kg/m2 (SD 3.0, range 25.6–
35.0  kg/m2). Mean HbA1c was well matched between 
the three treatment groups (all 7.41% [SD 0.61]). Mean 
SBP and DBP measurements were approximately 139 
and 84  mmHg, respectively. Mean LDL-cholesterol lev-
els were between 2.80 and 2.92  mmol/L; HDL-choles-
terol levels were 1.20  mmol/L. The majority of patients 
(40 patients, 95.2%) had concomitant diagnoses; the 
most frequent baseline condition was hypertension (23 
patients, 54.8%). Most patients (90.5%) reported con-
comitant therapy use, including ACE inhibitors (28.6%), 
statins (21.4%) and aspirin (7.1%). There were no differ-
ences in fasting and postprandial baseline flow-mediated 
vasodilation or baseline brachial artery diameter between 
the groups. Postprandial nitroglycerin-mediated vaso-
dilation was approximately four-fold higher than post-
prandial flow-mediated vasodilation, suggesting that 
endothelial smooth muscle cells were sensitive to nitric 
oxide.
Efficacy: vascular assessments
For the primary endpoint of change in fasting flow-medi-
ated vasodilation, the adjusted gMean ratios (90% CI) on 
day 28 to baseline were 0.89 (0.70–1.13) for linagliptin, 
1.00 (0.80–1.26) for glimepiride and 1.00 (0.79–1.28) for 
placebo (Fig.  2a). No statistically significant differences 
in fasting flow-mediated vasodilation were observed 
between the treatments (P > 0.1 for all comparisons).
For the secondary endpoint of change in postprandial 
flow-mediated vasodilation, the adjusted gMean ratios 
(90% CI) on day 28 to baseline were 1.26 (0.97–1.65) 
for linagliptin, 1.05 (0.82–1.34) for glimepiride and 1.01 
(0.78–1.31) for placebo (Fig. 2b). No statistically signifi-
cant differences in postprandial flow-mediated vasodila-
tion were observed between the treatments (P > 0.1 for 
all comparisons). For the change in postprandial nitro-
glycerin-mediated vasodilation, the adjusted mean ratios 
(90% CI) on day 28 to baseline were 1.00 (0.95–1.06) 
for linagliptin, 1.05 (1.00–1.11) for glimepiride and 0.98 
(0.92–1.04) for placebo. Differences between the treat-
ment groups were not statistically significant (P  >  0.1 
for all comparisons). For the primary and secondary 
endpoints, no effects associated with linagliptin were 
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identified when treatment effects were compared using 
an ANCOVA model adjusting for age (data not shown).
The changes in fasting and postprandial microcircula-
tory function, measured using laser-Doppler, are shown 
in Figs. 3, 4, 5. Under fasting conditions, minimal or no 
change from baseline in hyperaemia area was detected on 
day 28 with glimepiride or placebo treatment (adjusted 
mean [90% CI] ratio: glimepiride, 1.05 [0.89–1.22]; pla-
cebo, 1.13 [0.96–1.30]). Hyperaemia area increased by 
34% after linagliptin treatment on day 28 compared with 
baseline (1.34 [1.17–1.51]). This increase was statisti-
cally significant for the comparison versus glimepiride 
(P  =  0.0454; Fig.  3a). Postprandial hyperaemia area 
increased on day 28 compared with baseline in all three 
treatment groups (adjusted mean [90% CI] ratio: lina-
gliptin, 1.35 [1.12–1.57]; glimepiride, 1.16 [0.95–1.38]; 
placebo, 1.16 [0.94–1.39]). Differences between the treat-
ment groups were not statistically significant (Fig. 3b).
Resting blood flow under fasting conditions on day 28 
did not change from baseline with glimepiride or placebo 
treatment (adjusted mean [90% CI] ratio: glimepiride, 1.01 
[0.87–1.16]; placebo: 0.95 [0.79–1.10]). However, fast-
ing resting blood flow increased by 34% with linagliptin 
treatment (1.34 [1.19–1.50]). This increase was statisti-
cally significant for the comparison versus glimepiride 
(P  =  0.0108) and versus placebo (P  =  0.0026) (Fig.  4a). 
Postprandial resting blood flow increased by 18% with 
linagliptin and by 16% with glimepiride on day 28 com-
pared with baseline (adjusted mean [90% CI] ratio: lina-
gliptin, 1.18 (1.00–1.36); glimepiride, 1.16 [0.99–1.33]). 
Postprandial resting blood flow did not change with pla-
cebo treatment (0.99 [0.82–1.17]). Differences between the 
treatment groups were not statistically significant (Fig. 4b).
Peak blood flow under fasting conditions on day 28 did 
not change from baseline with glimepiride or placebo 
treatment (adjusted mean [90% CI] ratio: glimepiride, 
1.00 [0.89–1.11]; placebo: 0.96 [0.85–1.07]). However, 
fasting peak blood flow increased by 25% with linagliptin 
(1.25 [1.14–1.36]). This increase was statistically signifi-
cant for the comparison versus glimepiride (P = 0.0093) 
and versus placebo (P  =  0.0025) (Fig.  5a). Postprandial 
peak blood flow did not change from baseline with glime-
piride or placebo on day 28 (adjusted mean [90% CI] ratio: 
glimepiride, 1.02 [0.92–1.12]; placebo, 0.99 [0.88–1.09]). 
Postprandial peak blood flow increased by 11% with lina-
gliptin (1.11 [1.01–1.22]). Differences between the treat-
ment groups were not statistically significant (Fig. 5b).
Effect on levels of nitric oxide metabolites, vascular 
biomarkers, and cardiovascular risk factors
Compared with baseline, levels of fasting plasma glucose 
were decreased on day 28 with linagliptin or glimepiride 









Height (cm) 170.1 (8.6)
Body weight (kg) 87.7 (12.2)
Body mass index (kg/m2) 30.3 (3.0)
Hypertension (%) 54.8
Smoking status (%)














Patients (n) 40 41 40
HbA1c* (%) 7.41 (0.61) 7.41 (0.61) 7.41 (0.61)
FPG (mg/dL) 135.8 (3.7) 134.5 (3.1) 137.1 (4.2)
Lipids
 LDL cholesterol† (mmol/L) 2.80 (0.83) 2.92 (0.80) 2.80 (0.84)
 HDL cholesterol† (mmol/L) 1.20 (0.38) 1.20 (0.36) 1.20 (0.36)
 Total cholesterol† (mg/dL) 188.1 (17.1) 190.9 (16.3) 189.5 (16.4)
 Triglycerides† (mg/dL) 151.2 (46.9) 153.6 (45.7) 169.9 (134.8)
Brachial artery diameter (FMD)‡ (mm)
 Fasting, day −1 4.51 (0.56) 4.62 (0.60) 4.60 (0.58)
 day 28 4.50 (0.50) 4.52 (0.50) 4.53 (0.51)
 2-h postprandial, day −1 4.54 (0.52) 4.57 (0.61) 4.60 (0.64)
 day 28 4.49 (0.56) 4.59 (0.60) 4.51 (0.56)
Brachial artery diameter (NMD)‡ (mm)
 2-h postprandial, day −1 4.54 (0.55) 4.58 (0.63) 4.62 (0.60)
 day 28 4.52 (0.56) 4.60 (0.58) 4.57 (0.48)
SBP§ (mmHg) 138.8 (12.9) 139.3 (12.7) 138.8 (12.9)
DBP§ (mmHg) 84.2 (6.9) 84.2 (7.0) 84.2 (6.9)
Heart rate§ (bpm) 68.4 (9.5) 67.7 (9.8) 68.4 (9.5)
Values are mean (standard deviation) except where indicated
ACE angiotensin-converting enzyme, DBP diastolic blood pressure, FMD 
flow-mediated vasodilation, FPG fasting plasma glucose, HbA1c glycated 
haemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, NMD 
nitroglycerin-mediated vasodilation, SBP systolic blood pressure
* Determined at screening visit
† Lipids were determined on day −1 of each treatment period
‡ Post hoc analysis; linagliptin, n = 39; placebo, n = 39 on day 28
§ Determined at visit 1; linagliptin, n = 39; placebo, n = 39
























































(90% CI 0.715 1.397)
P = 0.9989
0.884
(90% CI 0.633 1.235)
P = 0.5403
0.884
(90% CI 0.632 1.235)
P = 0.5402
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(90% CI 0.721 1.485)
P = 0.8749
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Fig. 2 Change from baseline after 28 days between the three treatment groups in brachial endothelial-dependent macrocirculatory function using 
flow-mediated vasodilation (efficacy set). a Fasting. b 2-h postprandial. *Ratio of flow-mediated vasodilation on day 28 to flow-mediated vasodila-
tion at baseline. †n = 40 at baseline. CI confidence interval, FMD flow-mediated vasodilation
























































(90% CI 0.313, 0.160)
P = 0.5903
0.288
(90% CI 0.052 0.524)
P = 0.0454
0.212
(90% CI 0.025, 0.448)
P = 0.1404
0.182

























































(90% CI 0.311, 0.315)
P = 0.9927
0.184
(90% CI 0.129, 0.497)
P = 0.3310
Fig. 3 Change from baseline after 28 days between the three treatment groups in endothelial-dependent microcirculatory function using laser-
Doppler—hyperaemia area (efficacy set). a Fasting. b 2-h postprandial. *Ratio of hyperaemia on day 28 to hyperaemia at baseline. †n = 40 at 
baseline. ‡n = 38 at baseline. CI confidence interval


















































(90% CI 0.148, 0.276)
P = 0.6166
0.332
(90% CI 0.121 0.544)
P = 0.0108
0.396























































(90% CI 0.075, 0.415)
P = 0.2523
0.186
(90% CI 0.060, 0.431)
P = 0.2113
b
Fig. 4 Change from baseline after 28 days between the three treatment groups in endothelial-dependent microcirculatory function using laser-
Doppler—resting blood flow (efficacy set). a Fasting. b 2-h postprandial. *Ratio of resting blood flow on day 28 to resting blood flow at baseline. 
†n = 40 at baseline. ‡n = 38 at baseline. CI confidence interval




















































(90% CI 0.111, 0.196)
P = 0.6459
0.246
(90% CI 0.093 0.400)
P = 0.0093
0.289

























































(90% CI 0.111, 0.178)
P = 0.7008
0.126
(90% CI 0.019, 0.271)
P = 0.1510
b
Fig. 5 Change from baseline after 28 days between the three treatment groups in endothelial-dependent microcirculatory function using laser-
Doppler—peak blood flow (efficacy set). a Fasting. b 2-h postprandial. *Ratio of peak blood flow on day 28 to peak blood flow at baseline. †n = 40 
at baseline. ‡n = 38 at baseline. CI confidence interval
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treatment (P < 0.001 vs placebo for adjusted mean changes 
for both), whereas there was no change with placebo 
(Table 2). The greatest decrease was observed with glime-
piride treatment. Similar results were seen with changes 
in 2-h postprandial plasma glucose levels (P  <  0.001 vs 
placebo for adjusted mean changes for both linagliptin 
and glimepiride). Fasting and postprandial levels of insu-
lin increased with glimepiride treatment, whereas there 
was little or no change in these levels with linagliptin or 
placebo (Additional file 1: Table S1).
Levels of fasting and 2-h postprandial triglycerides 
decreased with linagliptin or glimepiride treatment, 
whereas there was no change with placebo (Table 2). No 
changes from baseline were observed in LDL- or HDL-
cholesterol levels under fasting or postprandial condi-
tions (Table  2). Fasting free fatty acid levels decreased 
with glimepiride treatment but not with linagliptin or 
placebo treatment (Additional file 1: Table S1). There was 
little or no change in postprandial free fatty acid levels 
across the treatment groups.
No changes in day or night mean SBP or DBP were 
detected after 28 days of placebo or linagliptin treatment. 
A slight increase in day and 24-h mean SBP was observed 
with glimepiride treatment after 28 days (Table 2). Both 
day and night mean heart rate increased by approxi-
mately 2 bpm after 28 days of linagliptin or glimepiride 
treatment. There was no change from baseline in mean 
heart rate with placebo (Table 2).
Changes in the levels of nitric oxide metabolites and 
vascular biomarkers under fasting or postprandial condi-
tions are included in Additional file 1: Tables S2 and S3. At 
the end of the study, no significant changes from baseline 
in fasting or postprandial nitrite and nitrate levels were 
seen across the treatment groups. Similarly, no significant 
Table 2 Cardiovascular risk factor levels at baseline and after 28 days (efficacy set)
Data are mean (standard error)
DBP diastolic blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, SBP systolic blood pressure, Day 07:00 to 23:00 h; night 23:00 to 07:00 h
* Some values at baseline are based on n = 40
†  Some values at day 28 are based on n = 40
Linagliptin 5 mg Glimepiride 1–4 mg Placebo
n = 39* n = 41† n = 39*
Baseline Unadjusted change 
from baseline at day 28
Baseline Unadjusted change 
from baseline at day 28
Baseline Unadjusted change 
from baseline at day 28
Plasma glucose fasting 
(mg/dL)
135.8 (3.7) −14.4 (2.4) 134.5 (3.1) −29.8 (3.6) 137.1 (4.2) −1.9 (2.0)
Plasma glucose 2-h post-
prandial (mg/dL)
179.8 (5.5) −19.7 (4.9) 178.7 (5.9) −37.3 (4.7) 183.3 (6.8) 0.2 (3.5)
Triglycerides fasting 
(mmol/L)
1.61 (0.10) −0.26 (0.08) 1.64 (0.09) −0.23 (0.10) 1.81 (0.24) 0.07 (0.10)
Triglycerides 2-h postpran-
dial (mmol/L)
1.78 (0.12) −0.32 (0.06) 1.81 (0.10) −0.21 (0.08) 1.95 (0.18) 0.02 (0.07)
LDL-cholesterol fasting 
(mmol/L)
2.80 (0.13) 0.00 (0.06) 2.92 (0.13) 0.04 (0.06) 2.80 (0.13) 0.00 (0.06)
LDL-cholesterol 2-h post-
prandial (mmol/L)
2.63 (0.12) 0.01 (0.05) 2.76 (0.12) 0.03 (0.06) 2.64 (0.13) 0.02 (0.05)
HDL-cholesterol fasting 
(mmol/L)
1.20 (0.06) 0.01 (0.02) 1.20 (0.06) 0.03 (0.02) 1.20 (0.06) 0.00 (0.02)
HDL-cholesterol 2-h post-
prandial (mmol/L)
1.13 (0.06) 0.02 (0.02) 1.13 (0.05) 0.03 (0.02) 1.15 (0.05) 0.01 (0.01)
Day SBP (mmHg) 136.9 (1.9) −0.1 (0.9) 136.0 (2.1) 1.9 (0.9) 135.7 (2.1) 0.2 (1.2)
Night SBP (mmHg) 124.5 (2.1) −0.8 (1.2) 126.2 (2.0) −0.2 (1.1) 124.5 (2.0) −0.1 (1.3)
24-h SBP (mmHg) 134.3 (1.8) −0.3 (0.9) 134.1 (2.0) 1.5 (0.9) 133.2 (2.0) 0.1 (1.1)
Day DBP (mmHg) 81.7 (1.3) 0.3 (0.5) 81.0 (1.4) 0.4 (0.6) 80.8 (1.5) 0.3 (0.6)
Night DBP (mmHg) 71.9 (1.4) −0.7 (0.8) 73.3 (1.5) −0.2 (0.6) 72.4 (1.4) −0.4 (0.7)
24-h DBP (mmHg) 79.7 (1.3) 0.1 (0.5) 79.5 (1.4) 0.2 (0.5) 79.1 (1.5) 0.1 (0.6)
Day heart rate (bpm) 78.5 (1.6) 2.7 (1.1) 77.8 (1.6) 1.8 (0.8) 77.4 (1.7) 0.5 (0.9)
Night heart rate (bpm) 68.9 (1.6) 2.0 (0.9) 69.1 (1.6) 1.9 (0.8) 69.3 (1.5) 0.4 (0.7)
24-h heart rate (bpm) 76.5 (1.6) 2.4 (1.0) 76.0 (1.6) 1.7 (0.7) 75.9 (1.6) 0.4 (0.8)
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changes from baseline were detected in the fasting levels 
of P-selectin, E-selectin or von Willebrand factor.
Safety
A summary of adverse events is presented in Table  3. 
Overall, fewer patients had treatment-emergent adverse 
events with linagliptin (11 patients, 27.5%) than with 
glimepiride (25 patients, 61.0%) or placebo (14 patients, 
35.0%). No adverse events of severe intensity were 
reported. The frequency of patients with adverse events 
deemed drug-related by the investigator was highest with 
glimepiride (18 patients, 43.9%). Adverse events leading 
to discontinuation of the trial drug were reported by 1 
patient (2.5%) receiving placebo. Adverse events of spe-
cial interest were reported by 2 patients (4.9%) receiving 
glimepiride and by 4 patients (10.0%) receiving placebo. 
There were no deaths or other serious adverse events 
during the treatment phases of the trial.
Investigator-reported hypoglycaemia occurred in 16 
patients (39.0%) on glimepiride, 2 patients (5.0%) on 
linagliptin, and 1 patient (2.5%) on placebo (Fig. 6). Most 
hypoglycaemic adverse events were symptomatic, with 
blood glucose levels between ≥3.0 and ≤3.9  mmol/L 
(≥54 and ≤70  mg/dL), or >3.9  mmol/L (>70  mg/dL). 
There were no cases of severe hypoglycaemia.
Discussion
This exploratory clinical trial was the first to com-
pare the effects of DPP-4 inhibition with sulphonylurea 
treatment and placebo on fasting and postprandial 
Table 3 Summary of adverse events (treated set)
MedDRA version 16.1 used for reporting
ICH International Conference on Harmonisation (E3 guideline)
* Pre-specified adverse events of special interest: hepatic injury, hypersensitivity reactions, skin lesions, renal adverse events and pancreatitis
Linagliptin 5 mg Glimepiride 1–4 mg Placebo
Patients (n) 40 41 40
Any adverse events (%) 27.5 61.0 35.0
Severe adverse events (%) 0.0 0.0 0.0
Drug-related adverse events (%) 17.5 43.9 10.0
Other significant adverse events (according to ICH E3) (%) 0.0 2.4 2.5
Adverse events leading to discontinuation of trial medication (%) 0.0 0.0 2.5
Adverse events of special interest* (%) 0.0 4.9 10.0
































Linagliptin n = 40
Glimepiride n = 41

















Fig. 6 Frequency of patients with investigator-reported hypoglycaemia (treated set). BG blood glucose
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macro- and microvascular endothelial function. The 
study was designed to assess the glucose-dependent and 
glucose-independent vascular effects of linagliptin in 
patients with T2D who were otherwise healthy and who 
were representative of a primary prevention cardiovascu-
lar disease population. As expected, both linagliptin and 
glimepiride reduced fasting and postprandial plasma glu-
cose levels after 28 days of treatment. Similarly, the safety 
findings were consistent with the known safety profiles 
of linagliptin and glimepiride. The overall frequency 
of adverse events was highest with glimepiride, mainly 
driven by the comparatively large number of hypoglycae-
mic episodes in the glimepiride group.
Effects on macrovascular function
Linagliptin or glimepiride treatment for 28 days did not 
significantly affect fasting or postprandial macrovascular 
endothelial function, as measured using flow-mediated 
vasodilation of the brachial artery. This finding is sup-
ported by the lack of change in the levels of several mark-
ers of macrovascular endothelial function (nitric oxide 
metabolites, P-selectin, E-selectin, von Willebrand fac-
tor). High-dose nitroglycerin was used as an exogenous 
nitric oxide donor to determine the maximum obtain-
able vasodilator response of the brachial artery. Because 
nitroglycerin-mediated vasodilation was substantially 
higher than flow-mediated vasodilation in the postpran-
dial state in all treatment groups, we can exclude that the 
lack of vasodilatory response after shear stress with flow-
mediated vasodilation was because of nitric oxide-insen-
sitivity of the vascular smooth muscle cells.
Based on existing evidence that acute reductions in 
hyperglycaemia may lead to improvements in endothelial 
function in T2D [19, 20], it is surprising that amelioration 
of macrovascular endothelial function was not observed 
with linagliptin or glimepiride in the present study. Pos-
sible explanations for this finding include the fact that 
the patients had relatively well controlled HbA1c levels 
(7.4%) and, therefore, the effects of glucotoxicity may not 
yet be contributing to endothelial dysfunction. In addi-
tion, the patients had uncomplicated T2D and no clinical 
indications of atherosclerosis, representing a population 
at a very early stage of diabetes-related vascular dysfunc-
tion and, in this state, linagliptin treatment may have lit-
tle or no impact on macrovascular endothelial function 
compared with patients with more advanced T2D and 
vascular dysfunction. The neutral effect in this primary 
prevention cardiovascular disease population is consist-
ent with a recent pooled analysis of randomised clinical 
trials of linagliptin that found no increase or decrease in 
cardiovascular event rates [21].
Other clinical studies evaluating the effects of DPP-4 
inhibition on endothelial function in patients with 
T2D have reported heterogeneous results. Vildaglip-
tin improved endothelial-dependent vasodilation in a 
4-week trial in 16 patients with T2D [16]. Several studies 
of sitagliptin have shown beneficial effects on endothe-
lial function in patients with T2D [17, 22], including 
patients with coronary artery disease [14, 23]. In con-
trast, two separate 6-week studies by Ayaori et al, showed 
that both sitagliptin and alogliptin significantly reduced 
endothelial function as measured by flow-mediated vaso-
dilation in 24 patients with T2D [13], while in a 12-week 
study in 42 patients with T2D (or impaired glucose toler-
ance) and acute coronary syndromes, sitagliptin did not 
affect endothelial function (measured using the reactive 
hyperaemia index) [24]. Sitagliptin also had no effect 
on macrovascular endothelial function measured by 
flow-mediated vasodilation and nitroglycerin-mediated 
vasodilation in a two-year study in T2D patients [25]. 
However, alogliptin slowed the progression of athero-
sclerosis (measured using intima media thickness of the 
carotid artery) in a 24-month study in 314 T2D patients 
with no apparent cardiovascular disease [26]. The incon-
sistent findings across these studies may be attributed 
to differences in the methodologies used to assess the 
changes in endothelial function, the impact of variations 
in trial durations, patient populations, background medi-
cations or the heterogeneous chemical nature of DPP-4 
inhibitors, for example [27].
Three large prospective trials in predominantly sec-
ondary prevention populations have shown that several 
members of the DPP-4 inhibitor class neither increased 
nor decreased the risk of cardiovascular events versus 
placebo [5–7]. An ongoing clinical trial (CAROLINA®; 
NCT01243424) will investigate differences in the effects 
on cardiovascular outcomes between linagliptin and 
glimepiride in patients with early T2D with mainly no 
established cardiovascular complications [28].
Effects on microvascular function
The noteworthy finding of the present study was that 
linagliptin improved measures of microvascular function 
in the fasting state—hyperaemia area, resting blood flow, 
peak blood flow—as determined after 28 days using laser-
Doppler blood flow assessments. Although the improve-
ment in hyperaemia area compared with placebo was not 
significant, this may reflect either high inter-day vari-
ability in resting blood flow [29] or type 2 error. Despite 
greater improvements in glycaemic control compared 
with linagliptin, no changes in microvascular function 
were detected with glimepiride, suggesting that linagliptin 
may exert beneficial effects on microvascular blood flow 
independent of glucose control. No effect was seen on 
postprandial microvascular function with either linaglip-
tin or glimepiride. One explanation for this latter finding 
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could be that postprandial endothelial dysfunction is trig-
gered by different mechanisms than fasting endothelial 
dysfunction (e.g., hyperglycaemia, hyperinsulinaemia, 
hypertriglyceridaemia or food toxins leading ultimately to 
increased oxidative stress [30–32]). Therefore, pleiotropic 
effects beyond metabolic changes may be more promi-
nent in the fasting than in the postprandial state.
The improvements in microvascular function seen in 
the present study are consistent with experimental stud-
ies using animal models, which have shown that linaglip-
tin has vasodilatory, anti-oxidant and anti-inflammatory 
properties, and can reduce atherosclerosis, independent 
of lowering glucose levels [33–35]. Preliminary clinical 
trials have also shown that linagliptin has the potential to 
modify microvascular function. In a randomised placebo-
controlled trial in 43 non-diabetes patients with a history 
of arterial hypertension, retinal microvascular blood flow 
was significantly improved after 12  weeks’ treatment 
with linagliptin [36]. No difference in the effect on gly-
caemic control was seen between the treatment groups. 
Similarly, linagliptin was shown to normalise increased 
renal endothelial function after 6  weeks’ treatment in 
a randomised placebo-controlled trial in 62 patients 
with T2D [37]. Most recently, a randomised placebo-
controlled, parallel-group study found that 12  weeks of 
treatment with linagliptin had no effect on macrovascu-
lar function, as measured by flow-mediated vasodilation 
and nitroglycerin-mediated vasodilation, but exhibited 
a trend towards improving microvascular function [38]. 
Taken together, this evidence suggests that linagliptin 
may improve microvascular function, which supports 
the results from several pooled analyses of phase III 
clinical trial data showing that linagliptin significantly 
reduced clinically relevant kidney disease endpoints in 
patients with T2D [39, 40]. Based on other clinical stud-
ies, it is unclear if improving microvascular function is 
a class effect of DPP-4 inhibitors: although vildagliptin 
improved retinal microvascular blood flow [41], saxaglip-
tin reduced retinal blood flow [15], and sitagliptin had no 
effect on skin microvascular function [42].
We propose several explanations that may account 
for the discordant effects of linagliptin on macro- and 
microvascular function seen in our study. Evidence from 
the UK Prospective Diabetes Study suggests that micro-
vascular complications emerge at a much earlier stage 
in T2D than macrovascular changes [43], and therefore, 
it is possible that the effects of linagliptin treatment on 
endothelial function may be minimal or strictly limited 
to the microvasculature in the present study given that 
the patient population had relatively uncomplicated T2D. 
In addition, the regulation of endothelial-specific pro-
cesses may vary between macro- and microvascular beds; 
for example, preclinical studies have shown a greater 
expression of the DPP-4 enzyme in the microvascula-
ture than in the macrovascular bed [44], a finding which 
suggests a more prominent role for DPP-4 in microvas-
cular endothelial function. This discordant effect on 
endothelial function seen in our study is supported by the 
results from a study in 39 patients who had similar clini-
cal characteristics to those in our study. In patients with 
T2D and no cardiovascular disease (but with mild dias-
tolic dysfunction), microvascular function was improved 
after 4 months of oral glucose-lowering therapy, whereas 
macrovascular function remained unchanged [45]. Taken 
together, this evidence suggests that the microvascula-
ture may benefit predominantly from DPP-4 inhibition 
in patients with early signs of vascular disease. Whether 
these benefits will extend to patients with albuminuria 
or more advanced renal microvascular disease is cur-
rently being evaluated in two prospective clinical trials 
of linagliptin—MARLINA-T2D™ (NCT01792518) and 
CARMELINA® (NCT01897532), respectively.
Limitations
This exploratory study has several strengths and limita-
tions. It was a single-centre study conducted in a rela-
tively low number of patients; however, the study was 
strengthened by its cross-over design and by the inclu-
sion of both active and placebo controls. The duration of 
treatment was only 4  weeks, which may be insufficient 
time for durable changes in endothelial function to occur 
in this particular study population. Patients’ use of addi-
tional medications (e.g., statins, ACE inhibitors) may have 
affected endothelial function. A post hoc subgroup analy-
sis found no significant differences in changes in flow-
mediated dilation, microvascular function, blood pressure 
or heart rate between patients taking ACE inhibitors 
(n = 12) and those not taking such medications (n = 30) 
(data not shown); however, the low patient numbers in 
these subgroups preclude firm conclusions on the poten-
tial confounding influence of ACE inhibitors. Assessment 
of microcirculation was not the primary or secondary 
endpoint; a large number of endpoints were assessed, 
leaving the possibility that the findings are because of 
an inflated alpha error. The study did not evaluate the 
mechanism(s) by which linagliptin may improve micro-
vascular function. Finally, the mean glimepiride dose 
taken during the study is not known, as the case report 
form used did not capture the number of tablets taken.
Conclusions
In patients with uncomplicated T2D and no clinical 
indications of macro- or microvascular complications, 
linagliptin but not glimepiride improved microvascu-
lar endothelial function in the fasting state. The effect 
appeared to be independent of glucose lowering and was 
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abolished by postprandial hyperglycaemia. Macrovas-
cular function was not affected by either linagliptin or 
glimepiride treatment. These results suggest that linaglip-
tin may improve microvascular endothelial function dur-
ing the early stages of diabetic vascular disease.
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